The FDA approved mFLUSIVA, Moderna's mRNA flu vaccine for adults 50 and older — the company's first product that isn't a COVID shot. A frozen federal vaccine committee and a collapsed revenue base mean it likely brings in nothing meaningful until 2027-28.

The FDA on Aug. 5 approved mFLUSIVA, Moderna's mRNA seasonal flu vaccine, for adults 50 and older — the first mRNA flu shot licensed in the U.S., and, notably, the first Moderna product on the market that isn't a COVID-19 vaccine. The SF Chronicle covered it as a consumer question — should older Bay Area residents take the new option? The more consequential question is what it does for a company that badly needs a second act.

The clinical case is real but modest. Full approval covers ages 50 to 64, backed by the 40,805-person Phase 3 FLUENT trial; the 65-and-up indication is an accelerated approval based on immunogenicity against a licensed high-dose shot, with a Phase 4 confirmatory trial still required. Efficacy came in around a 26.6% relative reduction in lab-confirmed flu versus a standard-dose comparator. The FDA's vaccine advisory panel voted 9-0 to endorse it back on June 18.

The balance sheet is the harder story. Moderna reported 2025 revenue of $1.9 billion, down roughly 40% year over year, and a GAAP net loss of $2.8 billion. It cut about $2.2 billion in operating expenses and roughly 10% of its workforce, then announced another 10% cut this year; Q2 2026 revenue was $145 million against a $782 million loss. CEO Stéphane Bancel — whose 2025 compensation was reported at $19.9 million — is steering toward cash breakeven by 2028.

mFLUSIVA won't get there. Moderna missed the 2026 vaccine contracting cycle, so it enters late against Sanofi, CSL Seqirus and GSK, which together hold more than 60% of the market. The list price hasn't been disclosed. And because a federal court injunction has frozen the CDC's immunization advisory committee since March, there's no formal recommendation — the mechanism that triggers automatic Medicare and insurance coverage. Jefferies analysts project only about $750 million in U.S. sales by 2030, with little before the 2027-28 season.

Watch three things: whether Moderna discloses a price before fall, whether the ACIP litigation resolves in time to matter for coverage, and whether Pfizer-BioNTech's competing mRNA flu shot reaches the FDA. The technology finally shipped beyond COVID. The revenue hasn't followed it yet.